In general, these discrepancies between the reported rates of cognitive decline in APOE4+ vs. APOE4− AD patients highlight the difficulty of trying to determine a consensus about the contributions of one single trait, such as APOE genotype, on the overall presentation of AD. The gene discussed is APOE; the disease is Alzheimer disease.